Table 2.
Relationship between treatment response and clinicopathological factors.
| Treatment response | Multivariates | ||||
|---|---|---|---|---|---|
| SD/PD | CR/PR | p | OR (95% CI) | p | |
| Age | |||||
| <60 | 58 (56.9%) | 44 (43.1%) | 1.000 | ||
| ≥60 | 11 (57.9%) | 8 (22.1%) | |||
| Gender | |||||
| Male | 67 (57.3%) | 50 (42.7%) | 1.000 | ||
| Female | 2 (50%) | 2 (50%) | |||
| Grade | |||||
| Well | 41 (53.2%) | 36 (46.8%) | |||
| Moderate | 24 (60%) | 16 (40%) | 0.165 | ||
| Poor | 4 (100%) | 0 (0%) | |||
| Stage | |||||
| IVa | 13 (37.1%) | 22 (62.9%) | 0.005 ∗ | 1 | |
| IVb | 56 (65.1%) | 30 (34.9%) | 0.310 (0.128–0.752) | 0.010 | |
| T stage | |||||
| 1/2 | 15 (53.6%) | 13 (46.4%) | 0.674 | ||
| 3/4 | 54 (58.1%) | 39 (41.9%) | |||
| N stage | |||||
| Negative | 16 (40.0%) | 24 (60.0%) | 0.008 ∗ | 1 | |
| Positive | 53 (65.4%) | 28 (34.6%) | 0.354 (0.151–0.834) | 0.017 | |
| Chemotherapy | |||||
| PF | 51 (63%) | 30 (37%) | 0.147 | ||
| TPF | 18 (45%) | 22 (55%) | |||
| Alcohol drinking | |||||
| Never | 17 (56.7%) | 13 (43.3%) | 0.964 | ||
| Yes | 52 (57.1%) | 39 (42.9%) | |||
| Smoking | |||||
| Never | 11 (37.9%) | 18 (62.1%) | 0.017 ∗ | ||
| Yes | 58 (63.0%) | 34 (37.0%) | |||
| Betel nuts | |||||
| Never | 16 (51.6%) | 15 (48.4%) | 0.480 | ||
| Yes | 53 (58.9%) | 37 (41.1%) | |||
| OPN | |||||
| Positive | 8 (29.6%) | 19 (70.4%) | 0.002 ∗ | 1 | |
| Negative | 61 (64.9%) | 33 (35.1%) | 0.320 (0.120–0.854) | 0.023 | |
CR, complete response; PR, partial response; SD, stable disease; PD, disease progression; PF, cisplatin/fluorouracil; TPF, docetaxel/cisplatin/fluorouracil; OR, odds ratio; CI, confidence interval.
∗Indicates significantly difference (p < 0.05).